162 results on '"Hoepping, Alexander"'
Search Results
2. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer
3. Preclinical and Clinical Aspects of Nicotinic Acetylcholine Receptor Imaging
4. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
5. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
6. Preclinical and Clinical Aspects of Nicotinic Acetylcholine Receptor Imaging
7. A new precursor for the preparation of 6-[18F]-fluoro-L-m-tyrosine (FMT): Efficient synthesis and comparison of radiolabeling
8. Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging
9. Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [18F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
10. Phase III study of18F-PSMA-1007 versus18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study
11. Synthesis of novel PSMA ligands and preclinical evaluation of [99mTc]TcO-ABX474, a radioligand for SPECT imaging of prostate cancer
12. Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results
13. Synthesis and biological evaluation of both enantiomers of [18F]flubatine, promising radiotracers with fast kinetics for the imaging of α4β2-nicotinic acetylcholine receptors
14. Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI
15. Radiosynthesis of racemic and enantiomerically pure (−)-[18F]flubatine—A promising PET radiotracer for neuroimaging of α4β2 nicotinic acetylcholine receptors
16. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.
17. An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging
18. Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [18F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
19. Synthesis of fluorine substituted pyrazolopyrimidines as potential leads for the development of PET-imaging agents for the GABA A receptors
20. An Explorative Study of the Incidental High Renal Excretion of [ 18 F]PSMA-1007 for Prostate Cancer PET/CT Imaging.
21. Radiosynthesis and biological evaluation of an 18F-labeled derivative of the novel pyrazolopyrimidine sedative–hypnotic agent indiplon
22. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
23. O-29 - Synthesis of novel PSMA ligands and preclinical evaluation of [99mTc]TcO-ABX474, a radioligand for SPECT imaging of prostate cancer
24. GABAA receptor pharmacology of fluorinated derivatives of the novel sedative-hypnotic pyrazolopyrimidine indiplon
25. A new precursor for the preparation of 6-[ 18F]Fluoro- l- m-tyrosine ([ 18F]FMT): efficient synthesis and comparison of radiolabeling
26. In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET)
27. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007—A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
28. Image-Guided Development of Heterocyclic Sulfoxides as Ligands for Tau Neurofibrillary Tangles: From First-in-Man to Second-Generation Ligands
29. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia
30. Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study †
31. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
32. Synthesis and biological evaluation of two novel DAT-binding technetium complexes containing a piperidine based analogue of cocaine
33. Dopaminergic agents for the treatment of cocaine abuse
34. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
35. Synthesis of a new HYNIC-DAPI derivative for labelling with ⁹⁹ᵐTechnetium and its in vitro evaluation in an FRTL5 cell line
36. In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET).
37. Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application
38. LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors
39. Development of a Novel Nonpeptidic 18F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography
40. Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications
41. Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study.
42. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.
43. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (−)-[18F]Flubatine
44. Synthesis of a new HYNIC-DAPI derivative for labelling with 99mTechnetium and its in vitro evaluation in an FRTL5 cell line
45. Internal Dose Assessment of (–)-18F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results
46. Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (−)-[18F]Flubatine in humans
47. Radiation dosimetry of the αβ nicotinic receptor ligand (+)-[F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.
48. LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine--A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors.
49. Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications.
50. Development of a Novel Nonpeptidic 18F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.